Henry and Hayes (72) provide an example of how incomplete reporting of specific types of chemotherapy received by patients with breast cancer could lead to different conclusions about the direction of the association between HER2 status and chemotherapy efficacy. The gene discussed is ERBB2; the disease is breast carcinoma.